U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Malignant Lymphoid Neoplasm

MedGen UID:
1767996
•Concept ID:
C5419563
•
Neoplastic Process

Definition

A malignant lymphoid neoplasm that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Malignant Lymphoid Neoplasm

Professional guidelines

PubMed

Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol 2022 Nov;97(11):1478-1488. Epub 2022 Sep 19 doi: 10.1002/ajh.26717. PMID: 36215668
World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J
Am J Hematol 2022 Jan 1;97(1):129-148. Epub 2021 Oct 8 doi: 10.1002/ajh.26352. PMID: 34533850
Cytokines in the Treatment of Cancer.
Conlon KC, Miljkovic MD, Waldmann TA
J Interferon Cytokine Res 2019 Jan;39(1):6-21. Epub 2018 Jun 11 doi: 10.1089/jir.2018.0019. PMID: 29889594Free PMC Article

Recent clinical studies

Etiology

World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J
Am J Hematol 2022 Jan 1;97(1):129-148. Epub 2021 Oct 8 doi: 10.1002/ajh.26352. PMID: 34533850
Diffuse Large B-Cell Lymphoma.
Sehn LH, Salles G
N Engl J Med 2021 Mar 4;384(9):842-858. doi: 10.1056/NEJMra2027612. PMID: 33657296Free PMC Article
How I treat warm autoimmune hemolytic anemia.
Barcellini W, Fattizzo B
Blood 2021 Mar 11;137(10):1283-1294. doi: 10.1182/blood.2019003808. PMID: 33512406
Acute lymphoblastic leukaemia.
Malard F, Mohty M
Lancet 2020 Apr 4;395(10230):1146-1162. doi: 10.1016/S0140-6736(19)33018-1. PMID: 32247396
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ
J Clin Oncol 2020 Jan 10;38(2):155-165. Epub 2019 Nov 6 doi: 10.1200/JCO.19.00172. PMID: 31693429Free PMC Article

Diagnosis

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H
Lancet Haematol 2023 Jan;10(1):e24-e34. Epub 2022 Nov 16 doi: 10.1016/S2352-3026(22)00319-2. PMID: 36402146
World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J
Am J Hematol 2022 Jan 1;97(1):129-148. Epub 2021 Oct 8 doi: 10.1002/ajh.26352. PMID: 34533850
How I treat warm autoimmune hemolytic anemia.
Barcellini W, Fattizzo B
Blood 2021 Mar 11;137(10):1283-1294. doi: 10.1182/blood.2019003808. PMID: 33512406
Hodgkin lymphoma.
Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL
Nat Rev Dis Primers 2020 Jul 23;6(1):61. doi: 10.1038/s41572-020-0189-6. PMID: 32703953
Acute lymphoblastic leukaemia.
Malard F, Mohty M
Lancet 2020 Apr 4;395(10230):1146-1162. doi: 10.1016/S0140-6736(19)33018-1. PMID: 32247396

Therapy

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H
Lancet Haematol 2023 Jan;10(1):e24-e34. Epub 2022 Nov 16 doi: 10.1016/S2352-3026(22)00319-2. PMID: 36402146
Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol 2022 Nov;97(11):1478-1488. Epub 2022 Sep 19 doi: 10.1002/ajh.26717. PMID: 36215668
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL
Lancet Oncol 2022 Aug;23(8):1055-1065. Epub 2022 Jul 5 doi: 10.1016/S1470-2045(22)00335-7. PMID: 35803286
Cytokines in the Treatment of Cancer.
Conlon KC, Miljkovic MD, Waldmann TA
J Interferon Cytokine Res 2019 Jan;39(1):6-21. Epub 2018 Jun 11 doi: 10.1089/jir.2018.0019. PMID: 29889594Free PMC Article
Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma.
Lunning MA, Vose JM
Blood 2017 Mar 2;129(9):1095-1102. Epub 2017 Jan 23 doi: 10.1182/blood-2016-09-692541. PMID: 28115369

Prognosis

Diffuse Large B-Cell Lymphoma.
Sehn LH, Salles G
N Engl J Med 2021 Mar 4;384(9):842-858. doi: 10.1056/NEJMra2027612. PMID: 33657296Free PMC Article
How I treat warm autoimmune hemolytic anemia.
Barcellini W, Fattizzo B
Blood 2021 Mar 11;137(10):1283-1294. doi: 10.1182/blood.2019003808. PMID: 33512406
Hodgkin lymphoma.
Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL
Nat Rev Dis Primers 2020 Jul 23;6(1):61. doi: 10.1038/s41572-020-0189-6. PMID: 32703953
Acute lymphoblastic leukaemia.
Malard F, Mohty M
Lancet 2020 Apr 4;395(10230):1146-1162. doi: 10.1016/S0140-6736(19)33018-1. PMID: 32247396
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ
J Clin Oncol 2020 Jan 10;38(2):155-165. Epub 2019 Nov 6 doi: 10.1200/JCO.19.00172. PMID: 31693429Free PMC Article

Clinical prediction guides

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H
Lancet Haematol 2023 Jan;10(1):e24-e34. Epub 2022 Nov 16 doi: 10.1016/S2352-3026(22)00319-2. PMID: 36402146
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL
Lancet Oncol 2022 Aug;23(8):1055-1065. Epub 2022 Jul 5 doi: 10.1016/S1470-2045(22)00335-7. PMID: 35803286
Hodgkin lymphoma.
Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL
Nat Rev Dis Primers 2020 Jul 23;6(1):61. doi: 10.1038/s41572-020-0189-6. PMID: 32703953
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A, Soma L
Cancer Treat Res 2019;176:127-144. doi: 10.1007/978-3-319-99716-2_6. PMID: 30596216
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH
N Engl J Med 2013 Apr 18;368(16):1509-1518. Epub 2013 Mar 25 doi: 10.1056/NEJMoa1215134. PMID: 23527958Free PMC Article

Recent systematic reviews

The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review.
Ridwansyah H, Wijaya I, Bashari MH, Sundawa Kartamihardja AH, Hernowo BS
Biomol Biomed 2023 Sep 4;23(5):727-739. doi: 10.17305/bb.2023.8791. PMID: 37004241Free PMC Article
Efficacy and Safety of Dual-Targeting Chimeric Antigen Receptor-T Therapy for Relapsed or Refractory B Cell Lymphoid Malignancies: A Systematic Review and Meta-Analysis.
Yu M, Zhang Q, Kong F, Qi L, Pu Y, Qiu L, Wang J, Li F
Hum Gene Ther 2023 Mar;34(5-6):192-202. doi: 10.1089/hum.2022.183. PMID: 36734417
Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
Wang Z, Zhou H, Xu J, Wang J, Niu T
Front Immunol 2022;13:1070660. Epub 2023 Jan 4 doi: 10.3389/fimmu.2022.1070660. PMID: 36685572Free PMC Article
Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis.
Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherril B, Ruiz-Soto R, Kaye JA, Hamadani M
J Oncol Pharm Pract 2016 Oct;22(5):666-78. Epub 2015 Aug 28 doi: 10.1177/1078155215603230. PMID: 26320127
Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis.
Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherrill B, Ruiz-Soto R, Kaye JA, Hamadani M
Clin Lymphoma Myeloma Leuk 2015 Apr;15(4):199-207. Epub 2014 Oct 2 doi: 10.1016/j.clml.2014.09.008. PMID: 25445467

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...